Yahoo
NasdaqGS - Nasdaq Real Time Price USD

COMPASS Pathways plc (CMPS)

13.62 +0.33 (+2.48%)
At close: July 2 at 4:00:01 PM EDT
13.79 +0.17 (+1.24%)
After hours: July 2 at 7:55:04 PM EDT
Trade CMPS on Coinbase
Chart Range Bar
Loading chart for CMPS
Chart does not reflect overnight price.
  • Previous Close 13.29
  • Open 13.36
  • Bid 9.83 x 200
  • Ask 16.52 x 200
  • Day's Range 12.78 - 13.80
  • 52 Week Range 3.24 - 15.40
  • Volume 4,073,093
  • Avg. Volume 4,406,511
  • Market Cap (intraday) 1.838B
  • Beta (5Y Monthly) 2.51
  • PE Ratio (TTM) --
  • EPS (TTM) -3.14
  • Earnings Date (est.) Jul 30, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 22.33

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

compasspathways.com

156

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 7/3/2026, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

CMPS
102.68%
MSCI WORLD (^990100-USD-STRD)
9.12%

1-Year Return

CMPS
302.96%
MSCI WORLD (^990100-USD-STRD)
19.77%

3-Year Return

CMPS
64.49%
MSCI WORLD (^990100-USD-STRD)
0.00%

5-Year Return

CMPS
63.46%
MSCI WORLD (^990100-USD-STRD)
58.70%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -39.71M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-40M
-20M
0

Analyst Insights

View More

Analyst Price Targets

8.00
22.33 Average
13.62 Current
70.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 6/26/2026
Analyst Canaccord Genuity
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 18 -> 20

Statistics

View More

Valuation Measures

Annual
As of 7/1/2026
  • Market Cap

    1.79B

  • Enterprise Value

    1.38B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    5.49

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -25.64%

  • Return on Equity (ttm)

    -68.48%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -192.36M

  • Diluted EPS (ttm)

    -3.14

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    466.01M

  • Total Debt/Equity (mrq)

    16.32%

  • Levered Free Cash Flow (ttm)

    33.07M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

13.62 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: